Expand chart
Data: S&P, Yahoo Finance; Chart: Andrew Witherspoon/Axios

The earnings and stock prices of health care companies have increased a lot more than the broader market since former President Obama signed the Affordable Care Act into law in 2010.

Between the lines: The ACA was designed to expand coverage and nudge companies toward new behaviors. But despite critics' warnings about the end of private insurance or a government takeover of health care, the law has not upended the system's underlying structure or stifled the industry's ability to reap large profits.

By the numbers: The S&P 500 health care index, which tracks the stocks of 63 major companies, has soared by 186% since the ACA became law. By comparison, the S&P 500 and Dow Jones increased by 141% and 139%, respectively, according to FactSet.

Winners: Health insurers. The stock price of Centene, a major Medicaid and ACA marketplace insurer, has multiplied by 12 times or 1,100%. Shares of UnitedHealth Group have jumped by more than 700%.

  • Insurers weathered cuts to Medicare Advantage and new requirements forcing them to cover sick people, but in return they got millions of taxpayer-subsidized customers through Medicaid expansion and the individual marketplaces.
  • Wall Street analysts say investors and companies were afraid the ACA was going to hurt the profitability of employer plans and Medicare Advantage. That never happened.
  • The individual marketplaces started out shaky but are now lucrative for the companies that remain. Medicare Advantage is expected to explode with growth over the next three years, and as more states expand Medicaid, more people get enrolled into private Medicaid plans.

The rest of the industry — which helped craft the law through intensive lobbying — has benefited, too.

  • Hospitals have faced sizable Medicare payment cuts from the ACA, but those reductions were largely offset by the law's Medicaid expansion and other forms of new coverage.
  • Rural hospitals, especially in states that have not expanded Medicaid, have struggled. Admissions also have stagnated. But the largest publicly traded hospitals (and big not-for-profit hospitals) have fared rather well.
  • The ACA did not meaningfully touch the pharmaceutical industry's business or patent practices, and those companies have reaped record profits. Pharma stocks over the past 8 years have fluctuated based on sales and new drug approvals, not on anything related to the ACA.
  • Medical device companies hate the ACA's device tax, but Congress has already deferred that fee a few times. The device tax hasn't hampered earnings and hasn't led to widespread job losses.

Go deeper: The ACA boom has helped pad the wallets of health care leaders.

Go deeper

Updated 1 hour ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 6 p.m. ET: 13,203,571 — Total deaths: 575,201 — Total recoveries — 7,331,068Map.
  2. U.S.: Total confirmed cases as of 6 p.m. ET: 3,407,798 — Total deaths: 136,252 — Total recoveries: 1,031,939 — Total tested: 41,004,275Map.
  3. Politics: Biden welcomes Trump wearing mask in public but warns "it’s not enough"
  4. Public health: Four former CDC heads say Trump's undermining of agency puts lives at risk — CDC director: U.S. could get coronavirus "under control" in 4–8 weeks if all wear masks.

Bank CEOs brace for worsening economic scenario

JPMorgan CEO Jamie Dimon. Photo: J. Lawler Duggan/For The Washington Post via Getty Images

Wells Fargo swung to its first loss since the financial crisis — while JPMorgan Chase and Citigroup reported significantly lower profits from a year earlier — as the banks set aside billions of dollars more in the second quarter for loans that may go bad.

Why it matters: The cumulative $28 billion in loan loss provisions that banks have so far announced they’re reserving serves as a signal they’re preparing for a colossal wave of loan defaults as the economy slogs through a coronavirus-driven downturn.

2 hours ago - Health

Moderna's vaccine spurred immune system response to coronavirus

Moderna's stock rose 16% after hours on this news. Photo: Jakub Porzycki/NurPhoto via Getty Images

Healthy volunteers who took Moderna's coronavirus vaccine candidate appeared to generate an immune system response to the virus, and there were "no trial-limiting safety concerns," according to a new study published in the New England Journal of Medicine.

Why it matters: The phase one trial is still small and does not definitively determine how effective the vaccine is. But Anthony Fauci of the National Institutes of Health, which is running the trial, told the Wall Street Journal that these data make it "pretty clear that this vaccine is capable of inducing quite good [levels] of neutralizing antibodies."